ABCL635 Cuts Menopausal Hot Flashes in a Small Phase 2 Trial
Menopausal vasomotor symptoms remain one of the most disruptive complaints in midlife care, and the burden is often felt long after the last menstrual period. Hot flashes and night sweats can fracture sleep, sap daytime energy, and erode concentration at work and at home. A new Phase 2 study now places ABCL635, a long-acting nonhormonal agent targeting the neurokinin 3 receptor, into that clinical conversation.
The signal was not subtle. In postmenopausal women with moderate-to-severe vasomotor symptoms, a single 600-mg subcutaneous dose produced a large reduction in hot flash frequency within four weeks, with benefit apparent by Week 1 and sustained through the end of follow-up.
Why the Neurokinin Pathway Matters in Menopause
The rationale for this drug class comes from thermoregulation biology rather than hormone replacement. Within the hypothalamus, KNDy neurons express neurokinin 3 receptors and participate in the circuitry that governs body temperature. When estrogen levels fall during the menopausal transition, signaling in this network changes, KNDy activity rises, and the thermoneutral zone narrows. In practical terms, the body becomes hypersensitive to minor temperature shifts, and that can trigger the sudden flushing, sweating, and heat sensation patients describe as hot flashes.
Blocking that pathway can calm the misfiring thermostat. Fezolinetant, an oral neurokinin 3 receptor antagonist, already established the clinical credibility of this approach when it received FDA approval in 2023 for moderate-to-severe menopausal vasomotor symptoms. ABCL635 takes a different route to the same receptor. It is a monoclonal antibody designed for longer persistence in the body, which creates the possibility of less frequent dosing than a daily oral agent.
The Trial Population and Dosing Strategy
The Phase 2 study was randomized, double-blind, and placebo-controlled. Ninety-two postmenopausal women were enrolled, and participants reported an average of about 10 moderate-to-severe hot flashes per day at baseline. Half received a single 600-mg subcutaneous dose of ABCL635, while the remainder received placebo.
The design matters because it tests both biological plausibility and bedside feasibility. A therapy that produces benefit after one injection, rather than requiring daily adherence, could be especially relevant for patients who dislike hormone therapy, cannot take it, or prefer to avoid chronic oral medication.
Frequency and Severity Both Moved in the Right Direction
At four weeks, women treated with ABCL635 experienced an average reduction of 8.8 moderate-to-severe hot flashes per day, compared with 3.5 episodes per day in the placebo group. The corresponding reductions were 83% with ABCL635 and 33% with placebo.
Severity improved as well. Mean hot flash severity fell by 1.4 points in the active-treatment group versus 0.3 points with placebo, translating to a 58% reduction with ABCL635 and 12% with placebo. Those parallel gains matter clinically because frequency alone does not capture the full burden of vasomotor symptoms; a shorter but equally intense flash can still disrupt a patient’s sleep or workday.
Improvement appeared quickly. Changes in both frequency and severity were seen as early as Week 1 and remained in place through Week 4. In a symptom-driven condition, that kind of early response can shape whether a patient stays with treatment long enough to judge benefit.
Sleep Improved Alongside Vasomotor Symptoms
Participants receiving ABCL635 also reported improvements in sleep. That finding fits the clinical pattern seen in menopausal care: nighttime vasomotor symptoms often amplify insomnia, and reduced hot flash burden can break that cycle. When sleep improves, daytime fatigue may soften as well, and patients often notice the difference in mood and cognitive clarity before they can quantify it.
The study also captured an overall assessment of symptom improvement, reinforcing the idea that women were not just counting fewer events on a diary. They were experiencing a meaningful shift in symptom burden.
Short-Term Safety Looked Acceptable, with Familiar Adverse Effects
Over four weeks, ABCL635 appeared well tolerated. No serious adverse events and no discontinuations due to adverse events were reported during the trial period. The most common adverse effects were headache, fatigue, and injection-site reactions, each occurring more often with ABCL635 than with placebo.
Short follow-up keeps interpretation tightly bounded. Four weeks can show whether a drug produces an early pharmacodynamic response and whether it triggers immediate intolerance, but it cannot establish what happens with repeated dosing, cumulative exposure, or rarer adverse events. For a long-acting antibody, those longer time points are not a side issue; they are central to whether the drug can move from promising signal to real-world option.
What This Means for Nonhormonal Menopause Care
Hormone therapy remains highly effective for menopausal vasomotor symptoms, but some women cannot use it and others do not want it. That gap has driven sustained interest in nonhormonal strategies, especially those that target the neurokinin system rather than estrogen pathways. ABCL635 is part of that shift.
The clinical appeal is straightforward. A long-acting injectable antibody could offer a nonhormonal alternative for women with frequent, bothersome hot flashes, while also potentially improving adherence compared with daily oral therapy. Yet the evidence base is still early. This was a small Phase 2 trial, and only 46 women received ABCL635. The sample is too limited to compare the drug meaningfully with existing treatments, and the short follow-up cannot answer questions about durability, optimal retreatment intervals, or safety across repeated use.
The biologic logic is strong, but the therapeutic position is not settled. In menopause care, symptom relief has to be balanced against tolerability, convenience, duration of effect, and long-term safety. ABCL635 delivered an encouraging first pass on those fronts, but the next studies will determine whether the benefit holds once the population is larger and the exposure window is longer.
One more point deserves emphasis. The most important data here are not just the magnitude of the hot flash reduction, but the speed of that response after a single injection. In a condition where women can be awakened multiple times each night and live with symptoms for years, an early and sustained effect is exactly the kind of result that justifies continued development.
For now, ABCL635 remains investigational. Larger trials will need to show whether the symptom control is durable, whether repeat dosing preserves the same tolerability profile, and whether the convenience of a long-acting antibody translates into a meaningful advantage in routine menopausal care.